IRLAB Therapeutics (Sweden) Performance
| IRLAB-A Stock | SEK 1.48 -0.10 -6.33% |
The firm holds a Beta of -0.65, which means generally lower market sensitivity than the broad market. As returns on the market increase, returns on IRLAB Therapeutics tend to move in the opposite direction, though by a smaller magnitude. During a bear market, however, IRLAB Therapeutics is likely to outperform the market. At this point, IRLAB Therapeutics has a negative expected return of -0.39%.
Risk-Adjusted Performance
Weak
Weak | Strong |
Over the last 90 days, IRLAB Therapeutics AB generated negative risk-adjusted returns and added little value for investors with long positions. Used correctly, this score supports evaluation of raw price movement versus actual return efficiency. Despite uncertain performance in the last few months, the stock's basic indicators remain somewhat strong, which may send shares a bit higher in April 2026. The current disturbance may also be a sign of long term up-swing for the company's investors. Learn More
| Begin Period Cash Flow | 277 M | |
| Total Cashflows From Investing Activities | -708 K |
IRLAB |
Relative Risk vs. Return Landscape
If you had invested kr 192.00 in IRLAB Therapeutics AB on December 24, 2025 and sold it today you would have lost kr 44.00 from holding IRLAB Therapeutics AB or given up 22.92% of portfolio value over 90 days. IRLAB Therapeutics AB is generating negative expected returns and shows 3.4585% volatility on return distribution over a 90-day horizon. Simply put, 31% of stocks are less volatile than IRLAB, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Target Price Odds to finish over Current Price
The tendency of IRLAB Stock price to converge on an average value over time is a well-known pattern in finance. Despite this pattern, historical data suggests that some stocks remain persistently mispriced until markets correct.
| Current Price | Horizon | Target Price | Odds moving above the current price in 90 days |
| 1.48 | 90 days | 1.48 | about 97.0 |
Based on a normal probability distribution, the odds of IRLAB Therapeutics moving above the current price in 90 days from now are about 97.0 . That keeps the near-term bias tilted toward stronger price outcomes for this stock. (The density curve centers on the price range the market has recently treated as most probable for IRLAB Stock over the next 90 days).
IRLAB Therapeutics Price Density |
| Price |
Predictive Modules for IRLAB Therapeutics
Numerous approaches exist for forecasting the stock market and estimating future values of IRLAB Therapeutics. Although accurate forecasting remains elusive, the process of modeling scenarios is a valuable part of decision-making.Experienced market participants anticipate that IRLAB Therapeutics' price will even out over time. Periods when IRLAB Therapeutics' deviates significantly from its historical mean may warrant further fundamental analysis.
Primary Risk Indicators
The last 10-20 years have been a volatile period for the stock market, and IRLAB Therapeutics is no exception. IRLAB Therapeutics has experienced periods of rapid price declines followed by equally strong recoveries.α | Alpha over Dow Jones | -0.4081 | |
β | Beta against Dow Jones | -0.65 | |
σ | Overall volatility | 0.16 | |
Ir | Information ratio | -0.0887 |
Investor Alerts and Insights
Automated alerts tied to IRLAB Therapeutics help investors stay ahead of material changes in stock conditions. IRLAB Therapeutics notifications flag important changes in technical indicators, fundamentals, and market conditions.| IRLAB Therapeutics generated a negative expected return over the last 90 days | |
| IRLAB Therapeutics may become a speculative penny stock | |
| IRLAB Therapeutics has high historical volatility and very poor performance | |
| About 39.0% of the company shares are held by company insiders |
Price Density Drivers
Price dynamics for IRLAB Stock are shaped by tension between bullish and bearish positioning among market participants. Key indicators for IRLAB Therapeutics capture the primary forces influencing short-term price behavior.
| Common Stock Shares Outstanding | 107.5 M | |
| Cash And Short Term Investments | 401.9 M |
IRLAB Therapeutics Fundamentals Growth
IRLAB Stock prices reflect investors' perceptions of IRLAB Therapeutics's future prospects and financial health. Revenue trajectory, earnings quality, profit margins, and leverage levels shape IRLAB Stock market performance.
| Return On Equity | -0.28 | |||
| Return On Asset | -0.15 | |||
| Profit Margin | -1.69 % | |||
| Operating Margin | -1.68 % | |||
| Current Valuation | 1.74 B | |||
| Shares Outstanding | 51.79 M | |||
| Price To Book | 6.24 X | |||
| Price To Sales | 33.49 X | |||
| Revenue | 207.78 M | |||
| EBITDA | 55.62 M | |||
| Cash And Equivalents | 401.9 M | |||
| Cash Per Share | 2.89 X | |||
| Total Debt | 3.57 M | |||
| Debt To Equity | 2.90 % | |||
| Book Value Per Share | 6.25 X | |||
| Cash Flow From Operations | 128.64 M | |||
| Earnings Per Share | 0.81 X | |||
| Total Asset | 472.45 M | |||
Performance Metrics & Calculation Methodology
IRLAB Therapeutics performance is measured on a risk-adjusted basis against benchmarks. Risk-adjusted measures provide context for return efficiency across regimes. IRLAB Therapeutics shows ROE of -27.69%, ROA of -14.79%.
Unless otherwise specified, data for IRLAB Therapeutics AB is compiled from periodic company reporting and market reference feeds and standardized for comparability. Updates may occur throughout the day. Return and risk statistics are calculated from historical price series.